Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis

NCT04634253 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04634253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04634253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
January 4, 2021
Completion date
June 29, 2022
Enrollment
98 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis